B-Cell Lymphomas
Information
- Disease name
- B-Cell Lymphomas
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05773040 | Active, not recruiting | Phase 1 | A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas | April 14, 2023 | December 31, 2027 |
| NCT01478269 | Completed | Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen | May 2009 | May 2011 | |
| NCT03218072 | Completed | Phase 1 | A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas | May 4, 2014 | January 31, 2015 |
| NCT01613300 | Completed | Phase 2 | Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients | April 4, 2012 | June 2020 |
| NCT02891590 | Completed | Phase 1 | Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas | September 2016 | February 2019 |
| NCT01068392 | Completed | Phase 2 | Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) | October 2009 | September 2014 |
| NCT01744912 | Terminated | Phase 1 | Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies | November 21, 2012 | February 7, 2014 |
| NCT02247609 | Unknown status | Phase 1/Phase 2 | Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas | January 2014 | October 2017 |
| NCT00801216 | Unknown status | Phase 2 | High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement | January 2007 | January 2012 |
| NCT05160064 | Withdrawn | Long-term Registry of Patients Treated With Loncastuximab Tesirine | June 30, 2022 | January 2025 |